You are here

Bi-specific Antibodies Targeting Disease Caused by Encephalitic Alphaviruses

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-C-0199
Agency Tracking Number: C181-007-0049
Amount: $149,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD181-007
Solicitation Number: 18.1
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-10-15
Award End Date (Contract End Date): 2019-04-14
Small Business Information
2222 MARONEAL ST #1616
United States
DUNS: 080446785
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Sandesh Subramanya
 (203) 848-0885
Business Contact
Phone: (203) 848-0885
Research Institution

Highly pathogenic alphaviruses like VEEV/EEV/WWEEV cause encephalitis in humans and equids. These infections are endemic in wide regions of the developing world. Translational research regarding these pathogens is focused on developing new strategies to detect, treat and ideally protect humans and animals from these infections. Gene-encoded antibodies against alphavirus E1/E2 surface proteins will be developed and evaluated, in this Phase I SBIR project, as therapeutic molecules. The intent of these studies is to create new antibody-based prophylactics that can neutralize VEEV infections. As a first step, we develop novel antibody fragments that bind specifically to their cognate antigen on surface of VEEV. We will also assess the relative performance and compatibility of delivery strategies for introduction of the antibody fragments across the blood brain barrier. These optimized formulations will be assessed for therapeutic benefit in future challenge studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government